AUA 2018: Which Patients Should Be Still Considered for Late Salvage Radiotherapy for Rising or Persistently Elevated PSA after Radical Prostatectomy?
San Francisco, CA (UroToday.com) Early administration of salvage radiation therapy (SRT) showed better outcomes compared to patients treated at a later stage with higher PSA levels. However, some patients may still respond to SRT even when PSA is higher. Nevertheless, it is currently unknown which of these patients may be still considered for late SRT, both in case of recurrent disease or persistently elevated PSA after surgery. In this study, the authors aimed at identifying optimal candidates for SRT among patients with PSA >0.5 ng/ml after radical prostatectomy (RP).
AUA 2018: The Prevalence and Biopsychosocial Predictors of Suicidality in Men with Prostate Cancer
San Francisco, CA (UroToday.com) Prostate cancer (PCa) is associated with a high rate of depression, more than that reported for the general population. There is a positive association between PCa diagnosis and suicide. The first aim of this study was to establish a point prevalence for suicidality among patients diagnosed with PCa. The second aim was to evaluate what biopsychosocial variables best predict greater risk of suicidality in men with PCa.
AUA 2018: Assessing the 20-Year Outcomes of Lymph Node Positive Prostate Cancer Patients: A Plea For Lifelong Follow-Up
San Francisco, CA (UroToday.com) Little data are available on oncological outcomes of lymph node metastatic (LNM) prostate cancer (PCa) patients at very long follow-up and on predictors of cancer specific mortality (CSM) in this setting. The authors evaluated the long-term patterns of clinical recurrence (CR) and CSM in a large database of surgically treated LNM PCa patients with at least 20 years of follow-up.
AUA 2018: Is Fatal Family History in Prostate Cancer a Predictor of Radical Prostatectomy Outcomes?
San Francisco, CA (UroToday.com) It is well known that a family history of prostate cancer, particularly of advanced or fatal disease, increases a man’s chance of being diagnosed with prostate cancer. In this single center study from Munich, Germany which was presented as a moderated poster at the American Urologic Association Annual Meeting, Dr. Herkommer and colleagues assessed the association between a first-degree family history of fatal prostate cancer and outcomes following radical prostatectomy for men diagnosed with prostate cancer.
AUA 2018: Association Between Environmental Quality and Prostate Cancer Stage at Diagnosis
San Francisco, CA (UroToday.com) Prostate cancer (PC) is reportedly up to 57% heritable, with the remainder attributed to exposures such as diet, medications, or environment. There are limited data regarding environmental exposures and PC aggressiveness, which was the focus of this study. Using the Surveillance, Epidemiology, and End Results (SEER) database the authors identified PC cases reported between 2010 and 2014.
AUA 2018: Oncological Outcomes of Salvage Radical Prostatectomy in a Contemporary, Multicentre Series of 395 Cases
San Francisco, CA (UroToday.com) While radical prostatectomy is the most commonly utilized treatment for clinically localized prostate cancer in the United States, many patients undergo other treatments including radiotherapy (whether external beam or brachytherapy), cryotherapy, high-intensity focused ultrasound (HIFU), and others. When patients who have undergone these treatments experience biochemical recurrence, management options are not well described. In a moderated poster presented at the American Urologic Association Annual Meeting, Dr. Gontero and colleagues report on a large, multi-institutional cohort from 18 tertiary care centers describing the outcomes of salvage radical prostatectomy in this setting. The authors present data relating to pre-operative, intra-operative, and post-operative factors including functional recovery following surgery.
AUA 2018: Non-Alcoholic Fatty Liver Disease in Men Undergoing ADT for Prostate Cancer
San Francisco, CA (UroToday.com) Androgen deprivation therapy (ADT) is associated with the development of diabetes and metabolic syndrome. However, its effect on the development of non-alcoholic fatty liver disease (NAFLD), a condition frequently accompanying metabolic syndrome, and other liver conditions have not been investigated. In this study, the authors analyzed the dose-dependent effect of ADT for localized prostate cancer on the risk of NAFLD, liver cirrhosis, hepatic necrosis, and any liver disease.